An article about Trefoil Therapeutics was included in the May 27 electronic version of a special Innovation in Ophthalmology Biopharma Dealmakers publication. Hard-copies will be published in mid-June.
The lead article is titled Partnering to Improve Vision and includes a short summary of the 100 ophthalmic transactions over the past five years.
The Trefoil article, Restoring Vision Loss with a Regenerative Therapy: One molecule, two products; how Trefoil Therapeutics engineered FGF1 (TTHX1114) to enable the treatment of multiple diseases affecting the cornea, can be found here.
The piece includes this excerpt:
The technology underlying Trefoil’s engineered FGF1, TTHX1114, builds on the well-known activities of native FGF1 to enable its use as a pharmaceutical for corneal diseases. FGF1 is a potent stimulator of cell proliferation and migration, and has cell protective properties, all key attributes for its use in endothelial disease (Fig. 1). The compound uniquely activates all seven forms of FGF receptors, contributing to its potency. Although FGF1’s activities are well known, native FGF1 has a short half-life, which renders it unsuitable as a pharmaceutical agent.
Read the full article.